{"title":"Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases","authors":"Kunal Malik , Emma Guttman-Yassky","doi":"10.1016/j.jisp.2017.10.005","DOIUrl":"10.1016/j.jisp.2017.10.005","url":null,"abstract":"<div><p>Alopecia areata is a T-cell-mediated disease that shares phenotypic similarities with other inflammatory diseases, particularly atopic dermatitis, and lacks safe, effective, mechanism-specific treatments. Increasing data suggests that alopecia areata harbors contributions of T helper type 1, T helper type 2, T helper type 17/IL-23, and phosphodiesterase pathways. Antagonism of these axes is undergoing evaluation, and might elucidate the underlying molecular circuitry of alopecia areata, advancing the translational revolution for this disease.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S62-S64"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35684148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica Cervantes , Joaquin J. Jimenez , Gina M. DelCanto , Antonella Tosti
{"title":"Treatment of Alopecia Areata with Simvastatin/Ezetimibe","authors":"Jessica Cervantes , Joaquin J. Jimenez , Gina M. DelCanto , Antonella Tosti","doi":"10.1016/j.jisp.2017.10.013","DOIUrl":"10.1016/j.jisp.2017.10.013","url":null,"abstract":"<div><p>Alopecia areata (AA) is an autoimmune disorder characterized by T lymphocytic infiltrates around the bulbar region of hair follicles. Statins have surfaced as potential therapeutic agents for AA, partly because of their modulation of the JAK/STAT pathway. Some data indicate that statins are a possible option for acute, but not chronic, longstanding AA. Animal studies suggest that treatment with statins increases CD4<sup>+</sup>/CD25<sup>+</sup>/Foxp3<sup>+</sup> populations in AA-affected mice.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S25-S31"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35683637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Alopecia Areata: The Clinical Situation","authors":"Maria K. Hordinsky","doi":"10.1016/j.jisp.2017.10.015","DOIUrl":"10.1016/j.jisp.2017.10.015","url":null,"abstract":"<div><p>In the absence of an approved treatment by the US Food and Drug Administration, choosing one of the many off-label treatments available for a child, teen, or adult with alopecia areata (AA) can be challenging. The physician or midlevel provider treating a patient with AA needs to take into consideration the age of the patient, location of hair loss, disease extent and activity, and any ongoing medical or psychological issues. Many patients and their families have now also heard the “buzz” about evolving research, particularly with JAK inhibitors, for the treatment of AA. This means that today’s clinic visit with the AA patient should include not only a discussion about traditionally used off-label treatments but also evolving therapies and clinical research opportunities.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S9-S11"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35684149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren C. Strazzulla , Lorena Avila , Kristen Lo Sicco , Jerry Shapiro
{"title":"An Overview of the Biology of Platelet-Rich Plasma and Microneedling as Potential Treatments for Alopecia Areata","authors":"Lauren C. Strazzulla , Lorena Avila , Kristen Lo Sicco , Jerry Shapiro","doi":"10.1016/j.jisp.2017.10.002","DOIUrl":"10.1016/j.jisp.2017.10.002","url":null,"abstract":"<div><p>Platelet-rich plasma and microneedling have been investigated recently as potential therapeutic options for the treatment of hair disorders. Evidence from laboratory studies indicates that these treatments enhance growth factor production that in turn facilitates hair follicle development and cycling. Several small studies and case reports have presented encouraging findings regarding the use of these treatments for alopecia areata. Future investigations will be needed to validate these therapeutic techniques for patients with alopecia areata and further refine which subtypes of the disease these methods are best indicated for.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S21-S24"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35683636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jordan M. Thompson , Min Kyung Park , Abrar A. Qureshi , Eunyoung Cho
{"title":"Race and Alopecia Areata amongst US Women","authors":"Jordan M. Thompson , Min Kyung Park , Abrar A. Qureshi , Eunyoung Cho","doi":"10.1016/j.jisp.2017.10.007","DOIUrl":"10.1016/j.jisp.2017.10.007","url":null,"abstract":"<div><p>Few studies have examined the clinical epidemiology of alopecia areata (AA) in regard to patient race, and therefore, any disparities in incidence or prevalence of disease are largely unexplored. We sought to investigate potential racial disparities amongst two large cohorts of women. We conducted a cross-sectional analysis from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII), wherein participants self-reported a diagnosis of AA. We determined odds ratios for AA by race in a multivariate analysis. Among 63,960 women from NHS and 88,368 women from NHSII with information on race and diagnosis of AA, we identified 418 and 738 cases of AA, respectively. In NHS, the multivariate-adjusted odds ratio for AA was 2.72 (95% confidence interval 1.61–4.61) amongst black women as compared with white women. In NHSII, the multivariate-adjusted odds ratio was 5.48 (95% confidence interval 4.10–7.32) amongst black as compared with white women. In a secondary analysis designating participants by Hispanic ethnicity, in NHSII the multivariate odds ratio was 1.94 (95% CI 1.24–3.02) in Hispanic compared with non-Hispanic white women. In this study, we found increased odds of AA based on self-reported race in black and Hispanic women as compared with white women. Further studies are needed to explore the mechanism of this racial disparity related to AA.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S47-S50"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35683642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Why Finding a Treatment for Alopecia Areata Is Important: A Multifaceted Perspective","authors":"Angela Renee Rodgers","doi":"10.1016/j.jisp.2017.10.008","DOIUrl":"10.1016/j.jisp.2017.10.008","url":null,"abstract":"<div><p>Alopecia areata is an autoimmune disease that alters one’s appearance. Some define it as a cosmetic disease despite evidence that substantial psychosocial burden is associated with it. As a physician, support group leader, consultant for the National Alopecia Areata Foundation, and patient, I discuss the evidence behind the psychosocial impact of alopecia areata and the importance of comprehensive treatment.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S51-S53"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35684145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current State of Research and Summary of Preceding Summits","authors":"David A. Norris","doi":"10.1016/j.jisp.2017.10.011","DOIUrl":"10.1016/j.jisp.2017.10.011","url":null,"abstract":"<div><p>During its 25th anniversary year, the National Alopecia Areata Foundation (NAAF) undertook a project to completely re-evaluate their research program and to help focus and direct future directions of alopecia areata (AA) research to better meet the goals of individuals with and the scientists working to discover mechanisms of disease and better treatments for AA. This project was embodied in five research summits in 2008, 2009, 2010, 2012, and 2014 as part of the NAAF’s main strategic initiative, the Alopecia Areata Treatment Development Program, to accelerate progress toward a viable treatment. The sixth summit, “Building and Crossing the Translational Bridge,” was held in 2016 and highlighted strong clinical data on the efficacy of topical and oral JAK inhibitors in mouse models and human AA. The advances discussed in this most recent summit provide real hope for a reliable and relatively safe treatment for AA. This work validates the last 10 years of research translating basic research of AA into new treatments based on the firm foundation of modern immunologic and genetic research.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S1-S2"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35684242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emerging Unconventional Therapies for Alopecia Areata","authors":"Natasha Atanaskova Mesinkovska","doi":"10.1016/j.jisp.2017.10.012","DOIUrl":"10.1016/j.jisp.2017.10.012","url":null,"abstract":"<div><p>Alopecia areata is a prevalent autoimmune skin disease with no cure or indicated treatment options. In the absence of an approved treatment, some patients are eager to try unconventional therapies, despite the very limited research evaluating their safety and efficacy. Recently emerging unconventional therapies for alopecia areata discussed include antihistamines, cryotherapy, and low-dose naltrexone.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S32-S33"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35683639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management","authors":"Ralf Paus , Silvia Bulfone-Paus , Marta Bertolini","doi":"10.1016/j.jisp.2017.10.014","DOIUrl":"10.1016/j.jisp.2017.10.014","url":null,"abstract":"<div><p>The collapse of the immune privilege (IP) of the anagen hair bulb is now accepted as a key element in AA pathogenesis, and hair bulb IP restoration lies at the core of AA therapy. Here, we briefly review the essentials of hair bulb IP and recent progress in understanding its complexity. We discuss open questions and why the systematic dissection of hair bulb IP and its pharmacological manipulation (including the clinical testing of FK506 and α-melanocyte-stimulating hormone analogs) promise to extend the range of future therapeutic options in AA and other IP collapse-related autoimmune diseases.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S12-S17"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35684245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}